Medicare participants stand to benefit from substantial reductions of up to 85% on the list prices of 15 widely prescribed blockbuster medications, with these newly negotiated rates set to activate in 2027, according to an announcement from the Centers for Medicare & Medicaid Services (CMS).
Had these negotiated prices been implemented during 2024, Medicare would have achieved savings of approximately $8.5 billion in net expenditures for covered prescription drugs, representing a roughly 36% decrease in overall spending, as detailed in a CMS fact sheet. Among the medications included in this initiative are well-recognized treatments like semaglutide, marketed under brand names such as Ozempic, Rybelsus, and Wegovy; palbociclib, known as Ibrance; and linaclotide, sold as Linzess. These agreements have secured prices that are as much as 85% lower than the original list prices. In 2024 alone, nearly 5.3 million individuals enrolled in Medicare Part D plans relied on these drugs to manage various health issues, including cancer, type 2 diabetes, and asthma, according to CMS data.
Furthermore, during 2024, Medicare Part D enrollees incurred about $1.7 billion in personal out-of-pocket expenses for these specific negotiated medications. Once the discounted rates come into play in 2027, CMS projects that beneficiaries will see their out-of-pocket costs drop by an estimated $685 million in that inaugural year of implementation.
This groundbreaking development stems from a legislative provision enacted by Congress in 2022 within the Inflation Reduction Act (IRA). This policy empowers Medicare to directly negotiate prescription drug prices, thereby driving down costs for older adults and enhancing affordability across the board.
Key Medications and Their Negotiated Prices
The roster of drugs subject to these negotiations encompasses a diverse array of treatments for serious conditions. Below is a comprehensive list highlighting each medication, its primary indications, and the dramatic price reductions:
- Semaglutide: Primarily prescribed for managing type 2 diabetes, obesity or overweight conditions, and cardiovascular disease. The list price for a 30-day supply stands at $959, while the negotiated price drops significantly to $274.
- Fluticasone furoate, umeclidinium, and vilanterol (Trelegy Ellipta): Indicated for chronic obstructive pulmonary disease (COPD) and asthma. List price is $654, negotiated to $175.
- Enzalutamide (Xtandi): Used in the treatment of prostate cancer. Original list price of $13,480 reduced to $7,004 under negotiation.
- Pomalidomide (Pomalyst): Addresses multiple myeloma and Kaposi sarcoma. List price $21,744 negotiated down to $8,650.
- Palbociclib (Ibrance): A key therapy for breast cancer. From a list price of $15,741 to a negotiated rate of $7,871.
- Nintedanib (Ofev): Treats idiopathic pulmonary fibrosis. List price $12,622 lowered to $6,350.
- Linaclotide (Linzess): Effective for irritable bowel syndrome with constipation and chronic idiopathic constipation. List price $539 becomes $136.
- Acalabrutinib (Calquence): Targets chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma. List price $14,228 negotiated to $8,600.
- Deutetrabenazine (Austedo, Austedo XR): Manages tardive dyskinesia and chorea associated with Huntington’s disease. List price $6,623 reduced to $4,093.
- Budesonide, glycopyrrolate, and formoterol fumarate (Breo Ellipta): For asthma and COPD. List price $397 drops to $67.
- Linagliptin (Tradjenta): Treats type 2 diabetes. From $488 list price to $78 negotiated.
- Rifaximin (Xifaxan): Prevents hepatic encephalopathy recurrence and treats irritable bowel syndrome with diarrhea. List price $2,696 to $1,000.
- Cariprazine (Vraylar): Indicated for schizophrenia, bipolar I disorder, and major depressive disorder. List price $1,376 negotiated to $770.
- Sitagliptin, metformin (Janumet, Janumet XR): For type 2 diabetes management. List price $526 reduced to $80.
- Apremilast (Otezla): Used for oral ulcers in Behçet’s disease, plaque psoriasis, and psoriatic arthritis. List price $4,722 to $1,650.
These reductions not only alleviate financial pressures on individual patients but also promise broader systemic savings for the Medicare program, making essential therapies far more accessible to those who need them most.
Official Statements and Leadership Perspectives
Health Secretary Robert F. Kennedy Jr. emphasized the administration’s commitment in a press release, stating that President Trump had instructed the team to pursue every possible avenue to reduce healthcare expenses for Americans. He further noted that in the effort to Make America Healthy Again, all available resources would be leveraged to provide cost-effective healthcare solutions specifically tailored for seniors.
Stakeholder Reactions and Broader Implications
Responses from various organizations and political figures have largely welcomed the announcement. AARP CEO Myechia Minter-Jordan, MD, MBA, highlighted in a statement that seniors from all political backgrounds prioritize lower drug costs, and these negotiations deliver substantial relief to millions of Medicare recipients. She expressed enthusiasm for the upcoming implementation of the initial round of price cuts starting January 1, 2026, and appreciated the administration’s safeguards to preserve Medicare’s negotiation capabilities for long-term benefits to older Americans.
Sen. Ron Wyden (D-Ore.), the ranking member of the Senate Finance Committee, reminded stakeholders that the drug price negotiation framework was a Democratic achievement. He pointed out that Democrats confronted pharmaceutical giants by granting Medicare negotiation authority on behalf of millions of seniors seeking affordable medications, despite unanimous Republican opposition in Congress. Wyden credited this Democratic initiative for the current advancements in reducing health expenses for the elderly, while criticizing Republicans for introducing delays and exemptions that undermine future negotiations, particularly for high-cost cancer treatments like pembrolizumab (Keytruda).
Even groups typically critical of the administration, such as Public Citizen, acknowledged the positive impact. Steve Knievel, the organization’s Access to Medicines Advocate, noted in a statement that the newly announced prices extend the triumphs of the prior negotiation round, projecting billions in annual savings for patients and taxpayers alike. Nonetheless, he cautioned that pharmaceutical companies and their congressional supporters persist in challenging the program, having already obtained a $9 billion concession through recent legislation funded by public and patient resources, with ongoing attempts to further postpone or exclude additional high-revenue drugs from negotiations.
It’s worth noting that even prior to the 2027 rollout of these 15 drugs, the discounts from Medicare’s first set of 10 negotiated medications will begin in January 2026. This earlier group includes options like dapagliflozin (Farxiga) for type 2 diabetes, heart failure, and chronic kidney disease; etanercept (Enbrel) for rheumatoid arthritis; and empagliflozin (Jardiance) for type 2 diabetes and heart failure, among several others. These phased implementations underscore a sustained strategy to progressively enhance affordability and access to critical prescription drugs within the Medicare framework.
